ORIC Oric Pharmaceuticals, Inc.
$9.00▲ +0.50%
Healthcare
Other
After hours
$9.00▲ +0.00%
Oct 27, 4:02 PM ET
Volume 4.94M
Avg Volume (10D) 1.97M
Key Metrics & Fundamentals
Market Cap
$932.87M
P/E Ratio
–
Div Yield
0.00%
52W Range
7.23 - 14.68
% vs 50 MA
-29.47%
% vs 200 MA
-19.32%
RSI-14
29.3
MACD Histogram
-0.3000
Beta (1Y vs SPY)
1.20
Free Cash Flow
-$31.96M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$45.03M
COGS
–
Operating Exp
$45.30M
Operating Income
-$45.30M
EBIT
-$45.30M
Pretax Income
-$41.49M
Net Income
-$41.49M
EPS (Diluted)
-0.38
Price & Volume History
Loading chart…
Recent News
ORIC Pharmaceuticals (ORIC) Stock Sees Modest Fair Value Lift On Trial Catalyst Optimism
Simply Wall St. · Oct 27, 2026 6:12 AM ET
Wedbush Adjusts Price Target on ORIC Pharmaceuticals to $14 From $17, Keeps Outperform Rating
MT Newswires · Oct 27, 2026 5:08 AM ET
ORIC Pharmaceuticals Sinks 22% as J&J Presents Rival Prostate Cancer Data
TIKR · Oct 26, 2026 12:39 PM ET
Oric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study
MarketBeat · Oct 23, 2026 1:04 PM ET
ORIC to Advance Lung Cancer Drug Candidate to Phase 3 Trial
MT Newswires · Oct 23, 2026 5:53 AM ET
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
GlobeNewswire · Oct 23, 2026 3:15 AM ET
ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
GlobeNewswire · Oct 23, 2026 3:15 AM ET
ORIC Stock In Focus As New Lung Cancer Trial Data Heads To ESMO 2026
Simply Wall St. · Oct 21, 2026 12:26 AM ET
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
GlobeNewswire · Oct 19, 2026 8:00 AM ET
Does ORIC (ORIC) Using Off‑Balance‑Sheet Funding for ORIC‑259 Redefine Its R&D Risk Strategy?
Simply Wall St. · Oct 8, 2026 1:12 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ORIC's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.